Psychedelic Microdosing: Prevalence and Subjective Effects.
TLDR
The findings suggest that psychedelic microdosing is relatively common and is subjectively associated with a broad spectrum of socio-affective, cognitive, and physical outcomes.Abstract:
Anecdotal reports suggest that the administration of sub-hallucinogenic doses of psychedelic compounds on a chronic, intermittent schedule – a practice known as psychedelic microdosing – is becomin...read more
Citations
More filters
Journal ArticleDOI
The Subjective Effects of Psychedelics May Not Be Necessary for Their Enduring Therapeutic Effects
TL;DR: Data is presented suggesting that the subjective effects induced by psychedelics may not be necessary to produce long-lasting changes in mood and behavior.
Journal ArticleDOI
Chronic, Intermittent Microdoses of the Psychedelic N,N-Dimethyltryptamine (DMT) Produce Positive Effects on Mood and Anxiety in Rodents
Lindsay P. Cameron,Charlie J Benson,Brian C. DeFelice,Oliver Fiehn,Oliver Fiehn,David E. Olson +5 more
TL;DR: It is found that chronic, intermittent, low doses of DMT produced an antidepressant-like phenotype and enhanced fear extinction learning without impacting working memory or social interaction.
Journal ArticleDOI
Trends in LSD use among US adults: 2015-2018
TL;DR: LSD use in the US jumped 56.4% from 2015 to 2018, and trends in LSD use were examined among adults in the United States, which can inform prevention and harm reduction efforts.
Journal ArticleDOI
Positive expectations predict improved mental-health outcomes linked to psychedelic microdosing
L S Kaertner,Michael B. Steinborn,Hannes Kettner,Meg J. Spriggs,Leor Roseman,T Buchborn,M Balaet,Christopher Timmermann,David Erritzoe,Robin L. Carhart-Harris +9 more
TL;DR: For instance, this article found that positive expectancy scores at baseline predicted subsequent improvements in well-being, suggestive of a significant placebo response, and highlighted a role for positive expectancy in predicting positive outcomes following psychedelic microdosing and cautions against zealous inferences on its putative therapeutic value.
Journal ArticleDOI
Toxicology and Analysis of Psychoactive Tryptamines.
Sara Malaca,Alfredo Fabrizio Lo Faro,Alice Tamborra,Simona Pichini,Francesco Paolo Busardò,Marilyn A. Huestis +5 more
TL;DR: The morbidity accompanying tryptamine intake is considerable and it is critical for clinicians and laboratorians to be informed of the latest data on this public health threat.
References
More filters
Journal ArticleDOI
Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010.
Harvey Whiteford,Harvey Whiteford,Louisa Degenhardt,Louisa Degenhardt,Juergen Rehm,Juergen Rehm,Amanda J Baxter,Amanda J Baxter,Alize J. Ferrari,Alize J. Ferrari,Holly E. Erskine,Holly E. Erskine,Fiona J Charlson,Fiona J Charlson,Rosana E. Norman,Rosana E. Norman,Abraham D. Flaxman,Nicole E. Johns,Roy Burstein,Christopher J L Murray,Theo Vos +20 more
TL;DR: The Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) as discussed by the authors was used to estimate the burden of disease attributable to mental and substance use disorders in terms of disability-adjusted life years (DALYs), years of life lost to premature mortality (YLLs), and years lived with disability (YLDs).
Journal ArticleDOI
Acute and Longer- Term Outcomes in Depressed Outpatients Requiring One or Several Treatment Steps: A STAR*D Report
A. John Rush,Madhukar H. Trivedi,Stephen R. Wisniewski,Andrew A. Nierenberg,Jonathan W. Stewart,Diane Warden,George Niederehe,Michael E. Thase,Philip W. Lavori,Barry D. Lebowitz,Patrick J. McGrath,Jerrold F. Rosenbaum,Harold A. Sackeim,David J. Kupfer,James F. Luther,Maurizio Fava +15 more
TL;DR: The acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial are described and compared.
Journal ArticleDOI
Cost of disorders of the brain in Europe 2010
Anders Gustavsson,Mikael Svensson,Frank Jacobi,Christer Allgulander,Jordi Alonso,Ettore Beghi,R. Dodel,Mattias Ekman,Carlo Faravelli,Laura Fratiglioni,Brenda Gannon,David P.H. Jones,Poul Jennum,Albena Jordanova,Linus Jönsson,Korinna Karampampa,Martin Knapp,Martin Knapp,Gisela Kobelt,Tobias Kurth,Roselind Lieb,Mattias Linde,Christina Ljungcrantz,Andreas Maercker,Beatrice Melin,Massimo Moscarelli,Amir Musayev,Fiona Norwood,Martin Preisig,Maura Pugliatti,Juergen Rehm,Luis Salvador-Carulla,Brigitte Schlehofer,Roland Simon,Hans-Christoph Steinhausen,Lars Jacob Stovner,Jean-Michel Vallat,Peter Van den Bergh,Jim van Os,Jim van Os,Pieter E. Vos,Weili Xu,Hans-Ulrich Wittchen,Bengt Jönsson,Jes Olesen +44 more
TL;DR: The present report presents much improved cost estimates for the total cost of disorders of the brain in Europe in 2010, covering 19 major groups of disorders, 7 more than previously, of an increased range of age groups and more cost items.
Journal ArticleDOI
Cost of disorders of the brain in Europe.
TL;DR: This paper presents a meta-anatomy of the immune system and its role in disease and injury in the context of clinical practice and shows clear patterns of decline in the aged and disabled.
Journal ArticleDOI
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.
TL;DR: When administered under supportive conditions, psilocybin occasioned experiences similar to spontaneously occurring mystical experiences, and the ability to occasion such experiences prospectively will allow rigorous scientific investigations of their causes and consequences.